Kennedy Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Kennedy Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7M	Sell	342,328 -9,974	-3%	-$322K	0.23%	161
2026 Q1	$11.2M	Buy	+352,302	New	+$9.6M	0.24%	157
2024 Q2	–	Sell	-33,586	Closed	-$1.41M	–	710
2024 Q1	$1.41M	Sell	33,586 -28,586	-46%	-$1.17M	0.03%	581
2023 Q4	$2.47M	Sell	62,172 -25,222	-29%	-$742K	0.05%	451
2023 Q3	$2.41M	Buy	87,394 +166	+0.2%	+$5.2K	0.06%	421
2023 Q2	$2.96M	Buy	87,228 +5,862	+7%	+$198K	0.07%	396
2023 Q1	$2.93M	Buy	81,366 +47	+0.1%	+$2.03K	0.09%	352
2022 Q4	$3.62M	Sell	81,319 -31	-0%	-$1.11K	0.1%	334
2022 Q3	$2.29M	Buy	81,350 +57,034	+235%	+$1.75M	0.07%	395
2022 Q2	$656K	Sell	24,316 -201	-0.8%	-$5.84K	0.02%	519
2022 Q1	$835K	Sell	24,517 -3,641	-13%	-$116K	0.02%	517
2021 Q4	$1.09M	Buy	+28,158	New	+$1.23M	0.02%	506

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's CLDX Position: Q2 2026 in Review

Kennedy Capital Management reduced its Celldex Therapeutics (CLDX) stake by 2.8% in Q2 2026, selling an estimated $322K and leaving 342,328 shares worth $12.7M. The position accounts for 0.23% of the portfolio, ranked #161.

Kennedy Capital Management first reported a position in CLDX in Q4 2021 and has held it in 12 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Kennedy Capital Management held 342,328 shares of Celldex Therapeutics worth $12.7M as of Q2 2026.
Kennedy Capital Management sold 9,974 Celldex Therapeutics shares in Q2 2026, an estimated $322K.
Celldex Therapeutics made up 0.23% of Kennedy Capital Management's portfolio in Q2 2026, its #161 holding.
Kennedy Capital Management first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 12 quarters since.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.